News

The real-world health benefits that cystic fibrosis (CF) patients experienced when they started taking Trikafta (elexacaftor/tezacaftor/ivacaftor) during the COVID-19 pandemic were caused by the medication itself rather than lockdown safety precautions, according to a new U.S. study. Because the U.S. Food and Drug Administration approved Trikafta in…

MRI images when a patient exhales may help detect and quantify areas presumed to reflect gas trapping — an early sign of lung disease — in people with cystic fibrosis (CF), including some patients with normal results on standard lung function tests, a study found. The imaging method also…

Macrophages from people with cystic fibrosis (CF) showed multiple defects that may make it harder for them to kill infectious bacteria, a new study reports. The findings also suggest that treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) partially improved CFTR function and corrected some macrophage functions, but was not enough to…

For people with cystic fibrosis (CF), the decision of whether or not to become a parent is fraught with psychological challenges, ranging from difficult fertility treatments to deep concerns about long-term health and family stigma, a new review paper highlights. The findings underscore the critical importance of providing comprehensive…

Immune abnormalities linked to lung inflammation and damage in people with cystic fibrosis (CF) may begin early in life and persist despite treatment, a study in Australia suggested. The study, led by researchers at the Murdoch Children’s Research Institute (MCRI) and the Peter MacCallum Cancer Centre, found widespread abnormalities…

Immune cells that patrol the lungs, called alveolar macrophages, may help sustain persistent inflammation in cystic fibrosis (CF), according to a new study. Researchers found that alveolar macrophages in people with CF differed from healthy cells, showing inflammatory activity, abnormal cholesterol handling, and altered communication with other immune cells…

People with cystic fibrosis (CF) treated with CFTR modulators have a significantly lower risk of death than untreated patients, with an overall 66% lesser risk over eight years, according to a large U.S. registry study. The survival benefit was similar in magnitude in males and females. “Our study is…

Data from continuous glucose monitoring (CGM) devices, which track blood sugar levels in real time, can reveal early signs of diabetes in people with cystic fibrosis (CF), even among those who test negative for diabetes using standard tools. That’s according to a study using machine learning, a type of…

ETD001, an inhaled therapy for cystic fibrosis (CF), appeared to work better than a placebo at improving lung function in CF patients not taking CFTR modulators — approved therapies that only work in people with certain CF-causing gene mutations — in a small clinical trial. That’s according to…

Blackstone Life Sciences is investing $250 million in Anagram Therapeutics to advance ANG003, an oral enzyme replacement therapy (ERT) for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). ANG003 is designed to reduce the “enormous, disruptive” pill burden for CF patients with EPI, which can amount…